PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE

Publication: <2002->: Basingstoke : Nature Publishing Group
Original Publication: Basingstoke, Hampshire, UK : Scientific & Medical Division, MacMillan Press, c1987-

Cell Transformation, Neoplastic/*pathology ; DNA-Activated Protein Kinase/*physiology ; DNA-Binding Proteins/*physiology ; Lymphoma/*etiology ; Mutation/*genetics ; Nuclear Proteins/*physiology ; Poly(ADP-ribose) Polymerases/*physiology ; Telomere/*physiology ; Tumor Suppressor Protein p53/*genetics; Animals ; Apoptosis ; Blotting, Western ; Cell Proliferation ; Cesium Radioisotopes ; Chromosome Aberrations ; DNA/genetics ; Female ; Genomic Instability ; Immunoenzyme Techniques ; In Situ Hybridization, Fluorescence ; Lymphoma/metabolism ; Lymphoma/pathology ; Male ; Mice ; Mice, Knockout ; Poly (ADP-Ribose) Polymerase-1 ; Radiation Tolerance/genetics ; Real-Time Polymerase Chain Reaction ; Thymocytes/metabolism ; Thymocytes/pathology ; Translocation, Genetic ; Tumor Cells, Cultured

Poly(ADP-ribose) polymerase 1 (PARP1) interacts genetically with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to suppress early-onset T-lineage lymphomas in the mouse, but the underlying mechanisms have remained unknown. To address this question, we analyzed a series of lymphomas arising in PARP1(-/-)/DNA-PKcs(-/-) (P1(-/-)/D(-/-)) mice. We found that, despite defective V(D)J recombination, P1(-/-)/D(-/-) lymphomas lacked clonal reciprocal translocations involving antigen-receptor loci. Instead, tumor cells were characterized by aneuploidy driven by two main mechanisms: p53 inactivation and abnormal chromosome disjunction due to telomere fusions (TFs). Aberrant accumulation of p53 was observed in 13/19 (68.4%) lymphomas. Sequence analysis revealed five p53 mutations: three missense point mutations (one transition in exon 8 and two transversions in exons 5 and 8, respectively), one in-frame 5-11 microindel in exon 7 and a 410-bp deletion encompassing exons 5-8, resulting in a truncated protein. Analysis of tumor metaphases using sequential telomere fluorescent in-situ hybridization and spectral karyotyping revealed that nine out of nine lymphomas contained TFs. Mutant but not wild-type p53 status was associated with frequent clonal and nonclonal TFs, suggesting that p53 normally limits the extent of telomere dysfunction during transformation. Chromosomes involved in TFs were more likely to be aneuploid than chromosomes not involved in TFs in the same metaphases, regardless of the p53 status, indicating that TFs promote aneuploidy via a mechanism that is distinct from p53 loss. Finally, analysis of radiation responses in P1(-/-)/D(-/-), and control primary cells and tissues indicates that loss of PARP1 increases in vivo radiosensitivity and genomic instability in DNA-PKcs-deficient mice without impairing p53 stabilization and effector functions, suggesting a more severe defect in double-strand break (DSB) repair in double mutants. Together, our findings uncover defective DSB repair leading to tumor suppressor inactivation and abnormal segregation of fused chromosomes as two novel mechanisms promoting tumorigenesis in thymocytes lacking PARP1 and DNA-PKcs.

Mol Cancer Res. 2010 May;8(5):701-16. (PMID: 20407015)
Oncogene. 1999 Aug 12;18(32):4616-25. (PMID: 10467406)
Curr Gerontol Geriatr Res. 2008;:754190. (PMID: 19415146)
Genes Dev. 1995 Mar 1;9(5):509-20. (PMID: 7698643)
Cell. 1995 Mar 10;80(5):813-23. (PMID: 7889575)
Mutat Res. 2009 May 12;664(1-2):20-7. (PMID: 19428377)
Science. 1991 Jul 5;253(5015):49-53. (PMID: 1905840)
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14899-904. (PMID: 10611310)
Trends Biochem Sci. 2010 Apr;35(4):208-19. (PMID: 20106667)
Nat Genet. 1997 Dec;17(4):479-82. (PMID: 9398855)
DNA Repair (Amst). 2004 Apr 1;3(4):349-57. (PMID: 15010310)
Oncogene. 2005 Feb 17;24(8):1328-37. (PMID: 15608683)
Oncogene. 2004 Sep 23;23(44):7322-9. (PMID: 15286704)
Immunity. 1998 Sep;9(3):355-66. (PMID: 9768755)
Genes Dev. 1999 Apr 15;13(8):916-34. (PMID: 10215620)
Cell. 2003 Aug 8;114(3):371-383. (PMID: 12914701)
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1520-7. (PMID: 19931734)
Oncogene. 2004 May 6;23(21):3872-82. (PMID: 15021907)
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. (PMID: 16829982)
Nat Cell Biol. 2005 Jul;7(7):706-11. (PMID: 15965466)
Mol Oncol. 2011 Aug;5(4):387-93. (PMID: 21821475)
Cell. 1997 Mar 7;88(5):593-602. (PMID: 9054499)
EMBO J. 2009 Sep 2;28(17):2601-15. (PMID: 19629035)
Science. 2001 Sep 28;293(5539):2462-5. (PMID: 11577237)
Nucleic Acids Res. 2003 Sep 1;31(17):4959-64. (PMID: 12930944)
Cancer Res. 2003 Sep 15;63(18):6008-15. (PMID: 14522929)
PLoS Genet. 2010 Aug 12;6(8):. (PMID: 20711355)
J Biol Chem. 1998 Jun 5;273(23):14461-7. (PMID: 9603959)
Science. 1996 Mar 22;271(5256):1744-7. (PMID: 8596939)
Cancer Res. 1998 Jul 15;58(14):3111-5. (PMID: 9679979)
Cell. 2010 Apr 2;141(1):81-93. (PMID: 20371347)
Blood. 2000 Sep 1;96(5):1940-6. (PMID: 10961898)
Mol Cell Biol. 2001 Jun;21(12):4046-54. (PMID: 11359911)
Immunity. 2008 Feb;28(2):231-45. (PMID: 18275833)
Science. 2009 Sep 4;325(5945):1240-3. (PMID: 19661379)
Nature. 1991 Jun 6;351(6326):453-6. (PMID: 2046748)
J Cell Biol. 2004 Nov 22;167(4):627-38. (PMID: 15545322)
Adv Immunol. 2008;99:33-58. (PMID: 19117531)
Nature. 2008 Oct 23;455(7216):1069-75. (PMID: 18948947)
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7303-7. (PMID: 9207086)
Nat Genet. 1999 Sep;23(1):76-80. (PMID: 10471503)
Cell. 2003 Aug 8;114(3):359-70. (PMID: 12914700)
Cell. 1999 May 14;97(4):527-38. (PMID: 10338216)
Mol Cell Biol. 1998 Nov;18(11):6457-73. (PMID: 9774662)
Science. 2002 Jul 26;297(5581):565-9. (PMID: 12142527)
Nat Rev Genet. 2010 May;11(5):319-30. (PMID: 20351727)
Mol Cell. 2006 Jan 20;21(2):201-14. (PMID: 16427010)
Annu Rev Genet. 2008;42:301-34. (PMID: 18680434)
Immunol Rev. 2003 Aug;194:77-95. (PMID: 12846809)
Mol Cell Biol. 2010 May;30(10):2341-52. (PMID: 20231360)
Cancer Res. 2001 Feb 1;61(3):912-5. (PMID: 11221881)
Mol Biol Cell. 2006 Apr;17(4):1686-96. (PMID: 16436506)
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13191-6. (PMID: 10557296)
Immunity. 1998 Sep;9(3):367-76. (PMID: 9768756)
Mol Cell Biol. 2007 Mar;27(6):2253-65. (PMID: 17145779)
J Biol Chem. 2000 Dec 29;275(52):40974-80. (PMID: 11016934)
Annu Rev Immunol. 1991;9:323-50. (PMID: 1910681)
Cell. 2002 Jun 28;109(7):811-21. (PMID: 12110179)
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3310-5. (PMID: 16492765)
Carcinogenesis. 1996 Dec;17(12):2537-42. (PMID: 9006086)
Hum Mol Genet. 2008 Sep 15;17(18):2910-8. (PMID: 18632684)
EMBO Rep. 2004 May;5(5):503-9. (PMID: 15105825)
Mol Cell. 2008 Jul 11;31(1):21-32. (PMID: 18614044)
J Exp Med. 2008 Mar 17;205(3):557-64. (PMID: 18316419)
Mol Cell Biol. 2001 Jun;21(11):3642-51. (PMID: 11340158)
Science. 1995 Feb 24;267(5201):1178-83. (PMID: 7855601)
Genes Dev. 1996 Aug 15;10(16):2038-54. (PMID: 8769647)
Cell. 2002 Apr;109 Suppl:S45-55. (PMID: 11983152)
EMBO J. 2002 Nov 15;21(22):6275-87. (PMID: 12426399)

P30 CA006973 United States CA NCI NIH HHS

0 (Cesium Radioisotopes)
0 (DNA-Binding Proteins)
0 (Nuclear Proteins)
0 (Tumor Suppressor Protein p53)
9007-49-2 (DNA)
EC 2.4.2.30 (Parp1 protein, mouse)
EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1)
EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
EC 2.7.11.1 (DNA-Activated Protein Kinase)
EC 2.7.11.1 (Prkdc protein, mouse)

Date Created: 20120523 Date Completed: 20130523 Latest Revision: 20211021

20250114

PMC4710090

10.1038/onc.2012.199

22614020